Ovarian cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Fahimeh Shojaei (talk | contribs)
nocaptcha, Administrators
5,051 edits
No edit summary
Fahimeh Shojaei (talk | contribs)
nocaptcha, Administrators
5,051 edits
No edit summary
Line 10: Line 10:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="2" rowspan="4" |Diseases
! colspan="2" rowspan="4" |Diseases
| colspan="8" |'''Clinical manifestations'''
| colspan="7" |'''Clinical manifestations'''
! colspan="4" rowspan="2" |Para-clinical findings
! colspan="4" rowspan="2" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Specific risk factors'''
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Age of onset'''
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Age of onset'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
Line 33: Line 32:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
|-
|-
! colspan="16" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Gynecologic
! colspan="15" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Gynecologic
|-
|-
| rowspan="15" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovary|Ovarian]]
| rowspan="15" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovary|Ovarian]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovarian cyst|Follicular cysts]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovarian cyst|Follicular cysts]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 54: Line 52:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovarian cyst|corpus luteum cysts]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovarian cyst|corpus luteum cysts]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 73: Line 70:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Serous cystadenoma/carcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Serous cystadenoma/carcinoma
| style="background: #F5F5F5; padding: 5px;" |>55 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* >55 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 91: Line 88:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mucinous cystadenoma]]/carcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mucinous cystadenoma]]/carcinoma
| style="background: #F5F5F5; padding: 5px;" |>55 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* >55 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 109: Line 106:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrioma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrioma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |+
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 118: Line 114:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Complex mass on US
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Complex mass on US
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 126: Line 122:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Teratoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Teratoma]]
| style="background: #F5F5F5; padding: 5px;" |10-30 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* 10-30 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 135: Line 131:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* High level of HCG and LDH
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 140: Line 137:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* It can cause ovarian torsion
* May content thyroid tissue and cause hyperthyroidism
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dysgerminoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dysgerminoma]]
Line 150: Line 150:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* High level of HCG and LDH
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Sheets fried egg appearance cells
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Same as male seminomas
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Choriocarcinoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Choriocarcinoma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 175: Line 176:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Yolk sac tumor]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Yolk sac tumor]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Young children
* Male infants
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 182: Line 185:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* High levels of AFP
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Yellow appearance
* Hemorrhagic
* Schiller-Duval bodies (glomeruli like structures)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* The other name is ovarian endodermal sinus tumor
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fibroma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fibroma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 206: Line 214:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thecoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thecoma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 222: Line 229:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Granulosa cell tumour|Granulosa cell tumor]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Granulosa cell tumour|Granulosa cell tumor]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 238: Line 244:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sertoli-Leydig cell tumor|Sertoli-leydig cell tumor]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sertoli-Leydig cell tumor|Sertoli-leydig cell tumor]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 254: Line 259:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brenner tumor]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brenner tumor]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 270: Line 274:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Metastasis]] ([[Krukenberg tumor|krukenberg]])
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Metastasis]] ([[Krukenberg tumor|krukenberg]])
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 287: Line 290:
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fallopian tube|Tubal]]
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fallopian tube|Tubal]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[tubo-ovarian abscess]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[tubo-ovarian abscess]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 303: Line 305:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ectopic pregnancy]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ectopic pregnancy]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 319: Line 320:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hydrosalpinx]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hydrosalpinx]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 335: Line 335:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]] [[salpingitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]] [[salpingitis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 351: Line 350:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Epithelial carcinoma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Epithelial carcinoma
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 367: Line 365:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |serous tubal intraepithelial neoplasm
| style="background: #DCDCDC; padding: 5px; text-align: center;" |serous tubal intraepithelial neoplasm
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 384: Line 381:
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterus|Uterine]]
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterus|Uterine]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Myoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Myoma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 400: Line 396:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sarcoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sarcoma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 416: Line 411:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pregnancy]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pregnancy]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 431: Line 425:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
! colspan="16" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Non-gynecologic
! colspan="15" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Non-gynecologic
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Gastrointestinal tract|GIT]]
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Gastrointestinal tract|GIT]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Appendix|Appendiceal]] [[abscess]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Appendix|Appendiceal]] [[abscess]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 451: Line 444:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Appendix cancer|Appendiceal  neoplasm]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Appendix cancer|Appendiceal  neoplasm]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 467: Line 459:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Diverticular abscess]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Diverticular abscess]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 483: Line 474:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Gastrointestinal tract|GI]] [[neoplasm]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Gastrointestinal tract|GI]] [[neoplasm]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 500: Line 490:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Renal]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Renal]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pelvic kidney]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pelvic kidney]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 517: Line 506:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Others
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Others
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Retroperitoneum|Retroperitoneal]] [[sarcoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Retroperitoneum|Retroperitoneal]] [[sarcoma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 20:48, 24 January 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer differential diagnosis

CDC on Ovarian cancer differential diagnosis

Ovarian cancer differential diagnosis in the news

Blogs on Ovarian cancer differential diagnosis

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Differentiating [Disease name] from other Diseases

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Age of onset Symptoms Physical examination
Lab Findings Imaging Immunohistopathology
pelvic pain or pressure vaginal discharge GI dysturbance Pleural effusion Fever Tendernes CT scan/US MRI
Gynecologic
Ovarian Follicular cysts
  • It is associated with hyperestrogenism and endometrial hyperplasia
corpus luteum cysts
  • Bilateral
  • Multiple
  • It is associated with hydatidiform moles and choriocarcinoma
Serous cystadenoma/carcinoma
  • >55 y/o
  • Bilateral
  • Most common ovarian neoplasm
Mucinous cystadenoma/carcinoma
  • >55 y/o
  • Can cause pseudomyxoma peritonei
Endometrioma +
  • Complex mass on US
  • Infertility
Teratoma
  • 10-30 y/o
  • High level of HCG and LDH
  • It can cause ovarian torsion
  • May content thyroid tissue and cause hyperthyroidism
Dysgerminoma
  • High level of HCG and LDH
  • Sheets fried egg appearance cells
  • Same as male seminomas
Choriocarcinoma
Yolk sac tumor
  • Young children
  • Male infants
  • High levels of AFP
  • Yellow appearance
  • Hemorrhagic
  • Schiller-Duval bodies (glomeruli like structures)
  • The other name is ovarian endodermal sinus tumor
Fibroma
Thecoma
Granulosa cell tumor
Sertoli-leydig cell tumor
Brenner tumor
Metastasis (krukenberg)
Tubal tubo-ovarian abscess fever and vaginal discharge
Ectopic pregnancy
Hydrosalpinx infertility
Tuberculosis salpingitis
Epithelial carcinoma
serous tubal intraepithelial neoplasm
Uterine Myoma
Sarcoma
Pregnancy
Non-gynecologic
GIT Appendiceal abscess
Appendiceal neoplasm
Diverticular abscess
GI neoplasm abdominal pain Intestinal obstruction and bleeding in small bowel,
Renal Pelvic kidney tract infection (UTI), obstruction, and renal calculi.
Others Retroperitoneal sarcoma Gastrointestinal symptoms, such as early satiety, obstruction,lower extremity edema, Serous ascites

check sites of cancer that may metastasize to the ovaries (eg, stomach, colorectal, breast)

check rectum, liver, spleen, lungs, inguinal or supraclavicular lymph nodes for ovary metastase

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Ovarian_cancer_differential_diagnosis&oldid=1540892"